Johnson & Johnson (NYSE:JNJ) Stock Holdings Reduced by Souders Financial Advisors

Souders Financial Advisors decreased its position in Johnson & Johnson (NYSE:JNJ) by 6.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,627 shares of the company’s stock after selling 448 shares during the period. Souders Financial Advisors’ holdings in Johnson & Johnson were worth $1,039,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares during the period. Morgan Stanley lifted its stake in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. Norges Bank purchased a new position in Johnson & Johnson during the fourth quarter worth about $4,609,399,000. Charles Schwab Investment Management Inc. boosted its stake in Johnson & Johnson by 1.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock valued at $3,046,449,000 after acquiring an additional 328,297 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Johnson & Johnson by 61.0% during the second quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock worth $1,868,351,000 after acquiring an additional 4,278,512 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Raymond James lifted their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, March 13th. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $148.78 on Friday. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The firm has a market capitalization of $358.53 billion, a P/E ratio of 10.77, a P/E/G ratio of 2.55 and a beta of 0.53. The stock has a 50 day moving average price of $157.42 and a two-hundred day moving average price of $156.08. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.91 and a current ratio of 1.16.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm’s revenue was down 9.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.35 EPS. Equities analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of Johnson & Johnson stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.